top of page
搜尋

ADCAN Pharma and Pinnacle Life Science agree licensing and technology-transfer deal for 12 oncology products

作家相片: nuaxia
nuaxia
9月3日
讀畢需時 1 分鐘

ADCAN Pharma and Pinnacle Life Science have entered into a licensing and technology-transfer partnership covering 12 oncology products and their planned local manufacture in the UAE.


The agreement combines product licensing with staged technology transfer intended to build local manufacturing capability for critical oncology medicines.


The partnership supports pharmaceutical localisation in the UAE while expanding ADCAN Pharma's oncology manufacturing portfolio.

Field

Content

Alert Type

Deal

Companies

ADCAN Pharma; Pinnacle Life Science

Deal Type

Licensing and technology-transfer agreement

Assets

12 oncology products

Therapy Area(s)

Oncology

Geography

United Arab Emirates

Deal Value

Financial terms were not disclosed

What Happened

ADCAN Pharma and Pinnacle Life Science entered into an agreement covering the licensing of 12 oncology products and staged transfer of manufacturing technology to the UAE.

Why It Matters

The partnership expands local access to oncology products while supporting the development of domestic pharmaceutical manufacturing capacity.

Strategic Rationale

ADCAN gains access to a broader oncology portfolio and manufacturing know-how, while Pinnacle extends its products into the UAE market through a local partner.

Potential Impact

Successful technology transfer could increase local production of oncology medicines and reduce dependence on imported supply.

Key Takeaway

The agreement combines licensing of 12 oncology products with a structured programme to transfer manufacturing capability into the UAE.

What to Watch

Completion of the technology-transfer stages, regulatory approvals and commencement of local manufacture.

Primary Source

ADCAN Pharma

Relevant Date

3 September 2026


Discover how nuaxia can support your next medical education initiative:

 
 
 

留言

評等為 0(最高為 5 顆星)。
暫無評等

新增評等
bottom of page